Journal
EXPERT REVIEW OF VACCINES
Volume 13, Issue 4, Pages 489-505Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1586/14760584.2014.894467
Keywords
vaccine; pathogenesis; Leishmania; arthropod
Categories
Funding
- NIAID
- NIH [P50AI074321]
- TMRC project
Ask authors/readers for more resources
Leishmaniasis is a neglected tropical disease spread by an arthropod vector. It remains a significant health problem with an incidence of 0.2-0.4 million visceral leishmaniasis and 0.7-1.2 million cutaneous leishmaniasis cases each year. There are limitations associated with the current therapeutic regimens for leishmaniasis and the fact that after recovery from infection the host becomes immune to subsequent infection therefore, these factors force the feasibility of a vaccine for leishmaniasis. Publication of the genome sequence of Leishmania has paved a new way to understand the pathogenesis and host immunological status therefore providing a deep insight in the field of vaccine research. This review is an effort to study the antigenic targets in Leishmania to develop an anti-leishmanial vaccine.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available